Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.
Rajshekhar Chakraborty, MD
Advertisement
Articles by Rajshekhar Chakraborty, MD
Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.
Advertisement
Latest Updated Articles
Insights Across Hematologic Oncology at Columbia UniversityMarch 16th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears At-Home HPV Self-Collection Kit to Expand Cervical Cancer Screening Access
2
FDA Lifts Partial Clinical Hold on Lorigerlimab for Gynecologic Cancer
3
Novel Nanoparticle May Improve SOC in Stage III Unresectable NSCLC
4
Targeting the Tumor Ecosystem to Create Pan–Solid Tumor Vulnerability
5